Showing 51–75 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Ian Links, Laurence J. Denholm, Marilyn Evers, L. Kingham, Robert J. Greenstein
BACKGROUND: Mycobacterium avium subsp. paratuberculosis (MAP) causes Johne's disease (or paratuberculosis), a chronic wasting disease of ruminants and other animals resulting from granulomatous enteritis. There are increasing concerns that MAP is zoonotic. The prevalence of Johne…
Sirak A, Tulu B, Bayissa B, Gumi B, Berg S, et al.
Local immunological responses at the site of infections, such as at the lymph nodes and lungs, do play a role in containing infection caused by Mycobacterium bovis ( M. bovis ). This bovine tuberculosis (bTB) study was conducted to evaluate cellular and cytokine responses in the …
Carter A, Msemburi W, Sim SY, Gaythorpe KAM, Lambach P, et al.
Background The Immunization Agenda 2030 (IA2030) Impact Goal 1.1. aims to reduce the number of future deaths averted through immunization in the next decade. To estimate the potential impact of the aspirational coverage targets for IA2030, we developed an analytical framework and…
Jeyachandran DS, Pusam Y
…how these insights could catalyze the development of future vaccines. The current landscape of novel vaccine development for TB is illuminated, including a spotlight on the latest vaccine candidates.
Gregor Nosan, Andreja Cerkvenik Škafar
…s to modernize TB prevention while awaiting next-generation vaccines and may serve as a guide for other low-incidence countries.
Samaila Aboubacar, Soumana Alido, Kamayé Moumouni, Mamoudou Abdou Djafar, Garba Moumouni, et al.
Introduction: Tuberculosis remains a public health problem worldwide. The BCG vaccination is one of the response means. The objective of this work was to study the impact of BCG vaccination on morbidity and mortality related to childhood tuberculosis in Niamey. Patients and metho…
Kanipe C, Putz EJ, Palmer MV
Bovine tuberculosis is mainly caused by Mycobacterium bovis. Bacillus Calmette-Guérin (BCG) is an attenuated strain of M. bovis which provides variable disease protection. Lesions have been characterized in infected cattle, but little comparison has been done with lesions which f…
Dijkman K, Lindenstrøm T, Rosenkrands I, Søe R, Woodworth JS, et al.
… resulting in ~1.6 million deaths annually. Protein subunit vaccines have shown promise against TB in clinical studies. Unfortunately, most subunit vaccines require multiple administrations, which increases the risk of loss to follow-up and necessitates more complex and costly lo…
Ian Links, Laurence J. Denholm, Marilyn Evers, L. Kingham, Robert J. Greenstein
Abstract Background Mycobacterium avium subsp. paratuberculosis (MAP) causes Johne’s disease (or paratuberculosis), a chronic wasting disease of ruminants and other animals resulting from granulomatous enteritis. There are increasing concerns that MAP is zoonotic. The prevalence …
Kwon KW, Choi HG, Kim KS, Park SA, Kim HJ, et al.
The quest for effective and enhanced multiantigenic tuberculosis (TB) subunit vaccine necessitates the induction of a protective pathogen-specific immune response while circumventing detrimental inflammation within the lung milieu. In line with this goal, we engineered a modified…
Ręka G, Korzeniowska A, Piecewicz-Szczęsna H
The aim of the study Is to present the state of knowledge from April and May 2020 about the influence of Bacillus-Calmette-Guérin vaccination against tuberculosis on incidence and mortality due to COVID-19. Material and methods A review of the latest literature till 9 May 2020 ha…
Wang H, Wang S, Fang R, Li X, Xing J, et al.
…fforts are underway to accelerate the development of new TB vaccines. However, challenges arise due to the limited immunogenicity and safety of these vaccines, necessitating adjuvants to bolster their ability to elicit a robust immune response for improved and safer immunization.…
Jessica E Rothman, Kenneth G Castro, Benjamin A Lopman, Neel R Gandhi, Kristin N Nelson
…to 2,486 (U.S.-born), within the range of established adult vaccines. **SUMMARY LINE:** Targeted vaccination of-infected high-risk persons with an M72/AS01-like vaccine could prevent one tuberculosis case per 217 (HIV) to 2,486 (U.S.-born) persons vaccinated, within the range of…
Wu Q, Zaid M, Xuan Z, Wang C, Gu H, et al.
…titis and tuberculosis, either by introducing adult booster vaccines or by research into more effective vaccines. Varicella and HFMD are on the rise, but vaccines for these are not included in national programs. Strategies funded by government agencies or encouraged by research i…
Angelidou A, Diray-Arce J, Conti MG, Smolen KK, van Haren SD, et al.
Vaccines have been traditionally developed with the presumption that they exert identical immunogenicity regardless of target population and that they provide protection solely against their target pathogen. However, it is increasingly appreciated that vaccines can have off-targe…
Wajja A, Namutebi M, Apule B, Oduru G, Kiwanuka S, et al.
…e for tuberculosis (TB) is a global public health priority. Vaccines under development will always need evaluation in endemic settings, most of which have limited resources. Adolescents are an important target population for a new TB vaccine and for other vaccines which are relev…
François Spertini, MD
…ion in inducing protection against tuberculosis (TB). Novel vaccines are essential to fight against the current world epidemics in tuberculosis and resistance to anti-TB drugs. A randomized, double-blind, controlled Phase I study conducted at CHUV, Lausanne, Switzerland, to comp…
Laura Sibley, Andrew White, Karen E. Gooch, Lisa Stevens, Rachel Tanner, et al.
Abstract This study describes the use of cynomolgus macaques of Chinese origin (CCM) to evaluate the efficacy and immunogenicity of the BCG vaccine against high dose aerosol Mycobacterium tuberculosis challenge. Progressive disease developed in three of the unvaccinated animals w…
Ebenezer Tumban
…-converting enzyme 2 receptor on the cells. Thus, candidate vaccines targeting the spike protein are currently being developed to prevent against infections. Approximately 44 SARS-CoV-2 candidate vaccines are in clinical trials (phase I-III) and an additional 164 candidates are i…
Blok BA, Arts RJW, van Crevel R, Aaby P, Joosten LAB, et al.
…inst tuberculosis, can potentiate immune responses to other vaccines through induction of trained innate immunity and heterologous adaptive immunity. We performed an explorative, randomized, noncontrolled open trial to investigate whether BCG vaccination increases humoral and cel…
Arif Khan, Asad Khan, Irfan Khan, Muhammad Aamir Shehzad, Waqar Ali, et al.
…transformation technique to form a transgenic plant. Edible vaccines grip countless promise as a profitable, easily managing, can be store easily, unlikely or unable to fail and sociocultural gladly sustainable, particularly for the poor emerging nations. An edible vaccine takes …
Vierboom MPM, Chenine AL, Darrah PA, Vervenne RAW, Boot C, et al.
…ated different routes of administration of vectored subunit vaccines based on chimpanzee-derived adenovirus serotype-3 (ChAd3) for homologous prime-boosting and modified vaccinia virus Ankara (MVA) for heterologous boosting with both vaccine vectors expressing the same antigens f…
Vasiliy Reshetnikov, Galina Shepelkova, Anna D. Rybakova, А. П. Трашков, Vladimir Yeremeev, et al.
mRNA vaccines turned out to be highly effective in combating the COVID-19 pandemic and other viral infections. Despite extensive study of mRNA vaccines in the last five years, the issue of safety of their use is still relevant. The study aimed to assess immunogenicity of two anti…
Pérez I, Uranga S, Sayes F, Frigui W, Samper S, et al.
…n a clinical isolate belonging to L4. Here we construct new vaccines based on isogenic gene deletions in clinical isolates of the L2 and L3 modern lineages. These three vaccine candidates were characterized at molecular level and also in animal experiments of protection and safet…
Özgül Kısa
…here isan urgent need for the development of alternative TB vaccines. Recently, new TB vaccine development efforts havebeen advanced in different clinical studies. Most of these vaccines are live-attenuated or recombinant mycobacterium,live viral vector-based, and protein/adjuvan…